Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2, Open-Label, Multi-Center, Dose Escalation and Expansion Study Evaluating the Safety, Tolerability and Clinical Activity of DECOY20 as Monotherapy and in Combination With Tislelizumab in Patients With Advanced Solid Tumors

NCT05651022 is registered in ClinicalTrials.gov with Indaptus Therapeutics, Inc as lead sponsor.

NCT NCT05651022
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05651022 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2, Open-Label, Multi-Center, Dose Escalation and Expansion Study Evaluating the Safety, Tolerability and Clinical Activity of DECOY20 as Monotherapy and in Combination With Tislelizumab in Patients With Advanced Solid Tumors
Lead sponsor
Indaptus Therapeutics, Inc
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
February 28, 2023
Completion date
September 30, 2027
Enrollment
120 (estimated)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

crc (colorectal cancer), hcc - hepatocellular carcinoma, msi-h cancer, nsclc non-small cell lung cancer, pancreatic adenocarcinoma, solid tumor, adult, squamous cell cancer of the head and neck, uc (urothelial cancer)